AKT1 and leukemia: Various inhibitors of PI3K or Akt currently under clinical studies [26], [28], [29] should be useful for chemosensitization of leukemias with tyrosine kinase domain mutations resistant to various inhibitors at least partly though downregulation of Chk1 activation.